跳至主要内容
临床试验/NCT01656824
NCT01656824Unknown不适用

Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年8月最近更新:
适应症

试验速览

阶段
不适用
入组人数
20
试验地点
1
主要终点
Tumor growth in xenograft model

研究概览

简要总结

Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil reduce the rate of growth of a primary human tumor implanted in the mice. we will take mice and transform their bone marrow cells into non-Bv8 producing cells. than we will implant primary human tumor tissue (taken from surgical specimens after informed consent)in those mice and follow-up on the mice.

详细描述

1-10 grams of human cancer tissue will be taken from surgical specimen without interference to the pathological data gathering process. those tissues will be implanted in nude mice that will either be treated with anti-Bv8 antibodies or will be transplanted with bone marrow in which Bv8 expression is silenced.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ages 18-85 years
  • Pathologically-confirmed diagnosis of pancreatic ductal adenocarcinoma undergoing surgical pancreaticoduodenectomy

排除标准

  • refuse to take part
  • preoperative chemotherapy

结局指标

主要结局

Tumor growth in xenograft model

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Tissue Study of Bv8/PK-2 Inhibition in Human Cancer | 临床试验